ISSUE 1558
| The full article is available to subscribers | Subscriber Login |
The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify is the first brimonidine product to be approved for OTC use.
PRESCRIPTION BRIMONIDINE PRODUCTS ― Brimonidine is available by prescription in higher-strength formulations both alone (Alphagan-P, and others) and in combinations with the beta blocker timolol (Combigan) and the carbonic anhydrase inhibitor brinzolamide (Simbrinza)1 for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Brimonidine is also available by prescription in a topical gel formulation (Mirvaso) for treatment of the facial erythema of
... more- Brinzolamide/brimonidine (Simbrinza) for glaucoma. Med Lett Drugs Ther 2013; 55:57.
- Brimonidine gel (Mirvaso) for rosacea. Med Lett Drugs Ther 2013; 55:82.
- GL Torkildsen et al. Evaluation of efficacy and safety of brimonidine tartrate ophthalmic solution, 0.025% for treatment of ocular redness. Curr Eye Res 2018; 43:43.
- According to walgreens.com. Accessed October 11, 2018.
- E McLaurin et al. Brimonidine ophthalmic solution 0.025% for reduction of ocular redness: a randomized clinical trial. Optom Vis Sci 2018; 95:264.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1558c
Electronic, downloadable article - $45
